AbbVie may count on Allergan's Botox for post-merger growth. But what else?

Botox Treatment
After a growth quarter for Allergan's Botox, AbbVie is looking at the drug as a post-merger business driver. (Getty Images)

With a $63 billion merger nearing approval, AbbVie is counting on Allergan and its cash-cow Botox to boost sales—and that superstar could be a long-term winner. But not every drug in Allergan's stable is shining quite so brightly. 

Cosmetic and therapeutic Botox combined for $927.8 million in global sales in the third quarter, a 5.8% increase over the previous year, Allergan said Tuesday. Cosmetic sales in the U.S. grew the most, delivering $237.6 million––a 10% increase from the previous year. 

Botox's success has been a point of pride for AbbVie as it seeks to close its merger with Allergan in early 2020 and add some fresh air to the new company's offerings. 

RELATED: Is AbbVie's Imbruvica concerned about AZ's rising Calquence? We've got this covered, execs say

Suggested Articles

Hospital-backed Civica Rx has struck a deal for a CDMO to help it develop its own brand of drugs, for which it will own the rights.

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.